News

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug

MicroStrategy’s Nasdaq Entry Kicks Off New Era of Momentum Risk

(Bloomberg) -- MicroStrategy Inc.’s entry into the Nasdaq 100 opens up the largest corporate holder of Bitcoin to a new — and untapped – investor: the index-tracking juggernauts. Most Read from BloombergHow California Sees the World, and ItselfYet Wall Street pros warn the oncoming march of these price-insensitive investors threatens a new source of vulnerability in a stock that has soared more than 500% this year on booming demand from retail investors, as well as hedge funds capitalizing on it